Licensing status

Publication and contact information

Assays & screens

Signature of 24 genes to predict prostate cancer recurrence

Sequencing studies identified a 24-gene panel that could help predict disease recurrence in patients with prostate cancer. In 106 prostate tumor samples, RNA sequencing led to the identification of a 24-gene signature that differentiated patients at high and low risk of disease recurrence when combined with assessment of clinical variables. In a validation dataset from 140 patients with prostate cancer, assessing clinical variables together with the 24-gene panel resulted in increased predictive capability of disease recurrence compared with assessing clinical variables alone or in combination with a gene signature from a panel of 31 cell-cycle progression genes. Next steps include validating the biomarkers in a larger patient cohort.

SciBX 7(19); doi:10.1038/scibx.2014.568
Published online May 15, 2014

Patent application filed; available for licensing

Long, Q. et al. Cancer Res.; published online April 8, 2014;
Contact: Carlos S. Moreno, Emory University, Atlanta, Ga.